p.78 抽出テキスト

356. Inoue H, Kodani E, Atarashi H, et al. J-RHYTHM Registry Investigators. Impact of body mass index on the prognosis of Japanese patients with non-valvular atrial fibrillation. Am J Cardiol 2016; 118: 215-221. PMID: 27255662 357. Hamatani Y, Ogawa H, Uozumi R, et al. Low body weight is associated with the incidence of stroke in atrial fibrillation patients - insight from the Fushimi AF registry. Circ J 2015; 79: 1009-1017. PMID: 25740669 358. Hohnloser SH, Pajitnev D, Pogue J, et al. ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W substudy. J Am Coll Cardiol 2007; 50: 2156- 2161. PMID: 18036454 359. Yamashita T, Suzuki S, Inoue H, et al. Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) registry. Eur Heart J Qual Care Clin Outcomes 2022; 8: 202-213. PMID: 33822030 360. Ogawa H, An Y, Ikeda S, et al. Fushimi AF Registry Investigators. Progression from paroxysmal to sustained atrial fibrillation is associated with increased adverse events. Stroke 2018; 49: 2301- 2308. PMID: 30355097 361. Ashburner JM, Go AS, Chang Y, et al. Effect of diabetes and glycemic control on ischemic stroke risk in AF patients: ATRIA study. J Am Coll Cardiol 2016; 67: 239-247. PMID: 26796386 362. Abdel-Qadir H, Gunn M, Lega IC, et al. Association of diabetes duration and glycemic control with stroke rate in patients with atrial fibrillation and diabetes: a population-based cohort study. J Am Heart Assoc 2022; 11: e023643. PMID: 35132863 363. Terauchi Y, Inoue H, Yamashita T, et al. Impact of glycated hemoglobin on 2-year clinical outcomes in elderly patients with atrial fibrillation: sub-analysis of ANAFIE registry, a large observational study. Cardiovasc Diabetol 2023; 22: 175. PMID: 37438827 364. Patti G, Lucerna M, Cavallari I, et al. Insulin-requiring versus noninsulin-requiring diabetes and thromboembolic risk in patients with atrial fibrillation: PREFER in AF. J Am Coll Cardiol 2017; 69: 409-419. PMID: 28126158 365. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864- 2870. PMID: 11401607 366. Adelborg K, Szépligeti S, Sundbøll J, et al. Risk of stroke in patients with heart failure: a population-based 30-year cohort study. Stroke 2017; 48: 1161-1168. PMID: 28377383 367. Witt BJ, Brown RD Jr, Jacobsen SJ, et al. Ischemic stroke after heart failure: a community-based study. Am Heart J 2006; 152: 102-109. PMID: 16824838 368. Alberts VP, Bos MJ, Koudstaal P, et al. Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol 2010; 25: 807-812. PMID: 21061046 369. Iguchi M, Tezuka Y, Ogawa H, et al. Incidence and risk factors of stroke or systemic embolism in patients with atrial fibrillation and heart failure ― the Fushimi AF registry. Circ J 2018; 82: 1327- 1335. PMID: 29526914 370. Hayashi K, Tsuda T, Nomura A, et al. Hokuriku-Plus AF Registry Investigators. Impact of B-type natriuretic peptide level on risk stratification of thromboembolism and death in patients with nonvalvular atrial fibrillation ― the Hokuriku-Plus AF registry. Circ J 2018; 82: 1271-1278. PMID: 29491320 371.  Akao M, Ogawa H, Masunaga N, et al. 10-year trends of antithrombotic therapy status and outcomes in Japanese atrial fibrillation patients ― the Fushimi AF registry. Circ J 2022; 86: 726- 736. PMID: 35283403 372.  Okumura K, Yamashita T, Suzuki S, et al. A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry). Clin Cardiol 2020; 43: 251-259. PMID: 31737921 373. Akao M, Yamashita T, Suzuki S, et al. Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF Registry subanalysis. Am Heart J 2020; 223: 23-33. PMID: 32135338 374. Shimizu W, Yamashita T, Akao M, et al. Renal function and clinical outcomes among elderly patients with nonvalvular atrial fibrillation from ANAFIE. JACC Asia 2023; 3: 475-487. PMID: 37396416 375. Del-Carpio Munoz F, Gharacholou SM, Munger TM, et al. Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation. Am J Cardiol 2016; 117: 69-75. PMID: 26698882 376. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821-2830. PMID: 22933567 377. Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial. Circulation 2016; 134: 24-36. PMID: 27358434 378. Nakagawara J, Ikeda T, Ogawa S, et al. Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function. J Cardiol 2019; 74: 501-506. PMID: 31371191 379. Böhm M, Ezekowitz MD, Connolly SJ, et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol 2015; 65: 2481- 2493. PMID: 26065986 380. Murakawa Y, Ikeda T, Ogawa S, et al. Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation. Heart Vessels 2020; 35: 1125-1134. PMID: 32253531 381. Boriani G, Ruff CT, Kuder JF, et al. Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. Eur Heart J 2019; 40: 1541-1550. PMID: 30624719 382. Park CS, Choi EK, Kim HM, et al. Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. Heart Rhythm 2017; 14: 501-507. PMID: 28042092 383. Lee SR, Choi EK, Park CS, et al. Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and low body weight. J Am Coll Cardiol 2019; 73: 919-931. PMID: 30819360 384. Kadosaka T, Nagai T, Suzuki S, et al. J-ELD AF investigators. Association of low body weight with clinical outcomes in elderly atrial fibrillation patients receiving apixaban-J-ELD AF registry subanalysis. Cardiovasc Drugs Ther 2022; 36: 691-703. PMID: 33830400 385. Kojima G. Frailty as a predictor of disabilities among community-dwelling older people: a systematic review and meta-analysis. Disabil Rehabil 2017; 39: 1897-1908. PMID: 27558741 386. 厚生労働省.基本チェックリスト.https://www.mhlw.go.jp/ topics/2009/05/dl/tp0501-1f_0005.pdf 387. Akishita M, Suzuki S, Inoue H, et al. Frailty and outcomes in older adults with non-valvular atrial fibrillation from the ANAFIE registry. Arch Gerontol Geriatr 2022; 101: 104661. PMID: 35303601 388. Wilkinson C, Wu J, Searle SD, et al. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. BMC Med 2020; 18: 401. PMID: 33357217 389. Segal JB, McNamara RL, Miller MR, et al. Prevention of thromboembolism in atrial fibrillation. a meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med 2000; 15: 56- 67. PMID: 10632835 390. Gumbinger C, Holstein T, Stock C, et al. Reasons underlying non-adherence to and discontinuation of anticoagulation in secondary stroke prevention among patients with atrial fibrillation. Eur Neurol 2015; 73: 184-191. PMID: 25633474 391. Nagata K, Inoue H, Yamashita T, et al. Impact of cognitive impairment on clinical outcomes in elderly patients with atrial fibrillation: ANAFIE registry. BMJ Neurol Open 2023; 5: e 000370. PMID: 36727104 392. Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation 2016; 133: 352-360. PMID: 26673560 393. Jaspers Focks J, Brouwer MA, Wojdyla DM, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ 2016; 353: i2868. PMID: 27306620 394. Alexander KP, Brouwer MA, Mulder H, et al. ARISTOTLE Investigators. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: insights from the ARISTOTLE trial. Am Heart J 2019; 208: 123-131. PMID: 30579505 395. Gutiérrez-Valencia M, Izquierdo M, Cesari M, et al. The relationship between frailty and polypharmacy in older people: a systematic review. Br J Clin Pharmacol 2018; 84: 1432- 1444. PMID: 29575094 396. Koretsune Y, Yamashita T, Akao M, et al. Baseline demographics and clinical characteristics in the All Nippon AF in the Elderly (ANAFIE) registry. Circ J 2 0 1 9 ; 8 3 : 1 5 3 8 - 1 5 4 5 . PMID: 31168044 397. Mannucci PM, Nobili A, Pasina L. REPOSI Collaborators. Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. Intern Emerg Med 2018; 13: 1191- 1200. PMID: 30171585